AbbVie makes milestone payment to Dragonfly after dosing in solid tumor trial

AbbVie made a milestone payment to Dragonfly Therapeutics, a clinical stage biotechnology company developing novel immunotherapies, following dosing of the first patient in a clinical trial to evaluate ABBV-303, a solid tumor targeting TriNKET. ABBV-303, an investigational drug being developed for the treatment of solid tumors, is the eighth drug using Dragonfly’s platform technology to enter the clinic, and the first AbbVie-licensed TriNKET drug candidate to enter into the clinic. The Phase 1 clinical trial, conducted by AbbVie, is evaluating ABBV-303 alone and in combination with AbbVie’s budigalimab in solid tumors.